NDC product
Azelastine Hydrochloride and Fluticasone Propionate
NDC 0378-3458 · Mylan Pharmaceuticals Inc.
Key facts
| Product NDC | 0378-3458 |
|---|---|
| Proprietary name | Azelastine Hydrochloride and Fluticasone Propionate |
| Nonproprietary name | Azelastine Hydrochloride and Fluticasone Propionate |
| Substances | AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE |
| Dosage form | SPRAY, METERED |
| Route | NASAL |
| Labeler | Mylan Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA202236 |
| Pharmacologic classes | Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC] |
| Marketing start | Apr 14, 2020 |
| Marketing end | Feb 28, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory